Anika Therapeutics (ANIK) Tops Q1 EPS by 27c ; Offers Guidance
Get Alerts ANIK Hot Sheet
Price: $19.20 -1.08%
EPS Growth %: +950.0%
Financial Fact:
Comprehensive income (loss): 9.26M
Today's EPS Names:
INM, TRI, CRVL, More
EPS Growth %: +950.0%
Financial Fact:
Comprehensive income (loss): 9.26M
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of $0.09, $0.27 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $40.5 million versus the consensus estimate of $41.55 million.
GUIDANCE:
Anika Therapeutics sees FY2024 revenue of $168-173 million, versus the consensus of $170.3 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c; Offers Guidance
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Sotera Health Co. (SHC) Tops Q3 EPS by 2c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share